Biogen (BIIB) PT Lowered to $262 at Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Reiterates Hold Rating on Biogen (BIIB), Notes CMS Decision "Closes The Door" for Aduhelm Coverage
April 8, 2022 6:07 AM EDTStifel analyst Paul Matteis reiterated a Hold rating on Biogen (NASDAQ: BIIB), following the final CMS coverage decision for beta amyloid mAbs.
The analyst notes: "CMS' final coverage decision for beta amyloid mAbs appears to be largely in-line with expectations--not much different from the... More
Biogen (BIIB) PT Lowered to $240 at Oppenheimer
April 8, 2022 5:07 AM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $240.00 (from $285.00) while maintaining a Outperform rating.... More
After-Hours Stock Movers 04/07: (MDVL) (WDFC) (PSFE) Higher; (BIIB) (CPT) Lower (more...)
April 7, 2022 6:03 PM EDTAfter-Hours Stock Movers:
MedAvail Holdings, Inc. (MDVL) 53% HIGHER; adds to today's 64% intra-day gains on carried-over momentum.
WD-40 Co. (NASDAQ: WDFC) 10% HIGHER; postedQ2 EPS of $1.41, $0.39 better than the analyst estimate of $1.02. Revenue for the quarter came in at $130 million... More
Biogen (BIIB) Alzheimer's Drug Coverage To Be Limited To Patients In Trials: CMS
April 7, 2022 4:49 PM EDT(Updated - April 7, 2022 4:55 PM EDT)
Biogen (NASDAQ: BIIB) shares were active after the market close on Thursday after CMS finalized its decision to pay for its Alzheimer's drug Aduhelm only in specified clinical trials, limiting payments.
... More